Controlled trial of the antigonadotropin danazol in painful nodular benign breast disease

Lancet. 1982 Apr 24;1(8278):928-30. doi: 10.1016/s0140-6736(82)91932-8.

Abstract

In a double-blind crossover study of the effects of the antigonadotropin danazol on pain and nodularity in 28 women with cyclical mastalgia danazol was given at doses of 200 mg/day and 400 mg/day, and the responses were assessed both subjectively and objectively. Danazol caused a significant and progressive decrease in breast pain and nodularity when compared with placebo. Symptoms responded more quickly with the 400 mg/day dose of danazol than with the 200 mg dose, but the larger dose also caused greater side-effects. Danazol is a useful addition to the range of antihormones that can be used to suppress the symptoms of severe hormone-related benign breast disease.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Breast Diseases / drug therapy*
  • Clinical Trials as Topic
  • Danazol / adverse effects
  • Danazol / pharmacology
  • Danazol / therapeutic use*
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Gonadotropins / antagonists & inhibitors*
  • Humans
  • Pain / drug therapy*
  • Pregnadienes / therapeutic use*
  • Random Allocation

Substances

  • Gonadotropins
  • Pregnadienes
  • Danazol